Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 3/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4242581 | 1.00 | MAPK13 (0.54) | MAPK13MAPK11CYP2C9MAPK12MAPK14 | |
| SCHEMBL13928965 | 0.84 | MAPK13 (0.70) | MAPK13MAPK11CYP2C9MAPK12MAPK14 | |
| SCHEMBL4240627 | 0.84 | MAPK13 (0.70) | MAPK13MAPK11CYP2C9MAPK12MAPK14 | |
| SCHEMBL4245997 | 0.77 | MAPK13 (0.63) | MAPK13MAPK11CYP2C9MAPK12MAPK14 | |
| SCHEMBL4243631 | 0.77 | MAPK13 (0.63) | MAPK13MAPK11CYP2C9MAPK12MAPK14 | |
| SCHEMBL4760829 | 0.77 | MAPK11 (0.77) | MAPK13MAPK11CYP2C9MAPK12MAPK14 | |
| SCHEMBL4245583 | 0.77 | MAPK11 (0.77) | MAPK13MAPK11CYP2C9MAPK12MAPK14 | |
| SCHEMBL4242576 | 0.76 | MAPK13 (0.69) | MAPK13MAPK11CYP2C9MAPK12MAPK14 | |
| SCHEMBL4236992 | 0.75 | MAPK13 (0.71) | MAPK13MAPK11CYP2C9MAPK12MAPK14 | |
| SCHEMBL5799317 | 0.74 | MAPK13 (0.70) | MAPK13MAPK11CYP2C9MAPK12MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042856-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | ASTELLAS PHARMA INC (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090042856-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | ASTELLAS PHARMA INC (JP) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042856-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | HRH2, OPRD1, HRH4 | MAPK13 1439/4885MAPK11 1195/4885CYP2C9 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.